In the phase II clinical trial TACTI-002 (NCT03625323), for NSCLC patients treated with the LAG3 inhibitor IMP321 combined with pembrolizumab, the ORR was 36% (57). The gene discussed is LAG3; the disease is non-small cell lung carcinoma.